Postmenopausal women with osteoporosis can find long-term benefit from bazedoxifene, which was found to be safe and effective over 7 years in a double-blind, osteoporosis treatment study of 7,492 generally healthy participants. The 2-year extension of the original 3-year core study, which found 20 mg and 40 mg dosages reduced the risk of new vertebral fractures by 42% and 37%, respectively, compared with placebo in postmenopausal women with osteoporosis, further determined:
• At 7 years, cumulative incidences of new vertebral fractures were significantly lower in the bazedoxifene (6.4%) and bazedoxifene 20 mg (7.6%) groups than in the placebo group (9.9%).
• Bazedoxifene had no effect on overall incidence of nonvertebral fractures.
• Mean changes from baseline in lumbar spine bone mineral density were 2.95%, 2.73%, and 2.19%.
• Bazedoxifene showed a favorable safety/tolerability profile across 7 years, with similar adverse events and serious adverse events.
Citation: Palacios S, Silverman S, de Villiers TJ, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause. 2015;22(8):806-813. doi: 10.1097/GME.0000000000000419.
This Week's Must Reads
Must Reads in Menopause
Menopause Symptom Burden and Chronic Pain, Menopause; ePub 2019 Mar 4; Gibson, et al
Trends in Menopausal Hormone Therapy, Menopause; ePub 2018 Dec 21; Crawford, et al
Chronic Disease Risk with Vaginal Estrogen Use, Menopause; ePub 2018 Dec 17; Bhupathiraju, et al
Sleep Disturbance After Surgical Menopause, Menopause; ePub 2018 Nov 12; Cho, Kim, et al
Cardiac Autonomic Function in Midlife Women, Menopause; ePub 2018 Jun 18; Fu, et al